We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BeyondSpring Inc (BYSI) USD0.0001

Sell:$1.80 Buy:$1.81 Change: $0.05 (2.84%)
Market closed |  Prices as at close on 16 April 2024 | Switch to live prices |
Sell:$1.80
Buy:$1.81
Change: $0.05 (2.84%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 16 April 2024 | Switch to live prices |
Sell:$1.80
Buy:$1.81
Change: $0.05 (2.84%)
Market closed |  Prices as at close on 16 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Contact details

Address:
100 Campus Drive
West Side, 4Th Floor, Suite 410
FLORHAM PARK
07932
United States
Telephone:
+1 (646) 5284184
Website:
https://www.beyondspringpharma.com/en/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BYSI
ISIN:
KYG108301006
Market cap:
$81.35 million
Shares in issue:
39.02 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
Cayman Islands
Currency:
US dollar
Indices:
n/a

Key personnel

  • Lan Huang
    Chairperson of the Board, Chief Executive Officer, Co-Founder
  • G. Kenneth Lloyd
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.